Updated CanREValue Interim Data Report now available!

/0 Comments/in , /by
As part of a broader engagement strategy, the CanREValue Collaboration has launched a stakeholder consultation process. In late 2019, the CanREValue Collaboration undertook public stakeholder consultation regarding the Interim Data Report developed by the CanREValue Data Working Group. From this consultation, we received 20 constructive submissions from a diverse set (more…)

New Publication: Real-world comparative effectiveness of 2nd line ipilimumab for metastatic melanoma…

/0 Comments/in , /by
ARCC and the CanREValue Collaboration are excited to share our recent study, using Ontario based real-world data to generate real-world evidence on the comparative effectiveness of 2nd line ipilimumab. Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada  Dai WF,  Beca JM, Croxford (more…)

CanREValue Interim Methods Report Open for Feedback

/0 Comments/in , , /by
The CanREValue Collaboration is pleased to open the feedback consultation period for our Methods Working Group report: CanREValue Collaboration Methods Working Group Progress Report on Real World Survival Data. View the Methods Working Group Report here Feedback Form Stakeholder input is essential to the development of a framework for the incorporation (more…)

New Publication: Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

/0 Comments/in /by
We are excited to report the publication of our manuscript Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration with BMJ Open. View the Article online with BMJ by clicking here Download a PDF copy directly by clicking (more…)

CanREValue Interim Policy Report Open for Feedback

/0 Comments/in , , /by
The CanREValue Collaboration is pleased to open the feedback consultation period for our Policy Working Groups: Developing a framework for incorporating real-world evidence into drug funding decisions: CanREValue Collaboration Policy Working Groups Interim Report 2019. View the Policy Working Groups Report here View the Report Appendix here Feedback Form Stakeholder input is (more…)

CanREValue Interim Data Report Open for Feedback

/0 Comments/in , , /by
The CanREValue Collaboration is pleased to open the feedback consultation period for our first Data Working Group Interim Report: Mapping Canadian Provincial Data Assets to Conduct Real-World Studies on Cancer Drugs. View the Interim Data Working Group Report here View the Report Appendix here Feedback Form We welcome any stakeholder (more…)

Engagement Webinar Recording & Slides Now Available

/0 Comments/in /by
We have now uploaded a copy of the slides and a full recording of our Stakeholder Engagement Webinar which was held on Wednesday November 6th 2019. View a copy of the slide deck here Listen to & watch the recorded webinar here Please feel free to share these links with (more…)

Article: Is There Evidence in Real-World Evidence?

/0 Comments/in /by
“Evidence from real-world practice and utilization—outside of clinical trials—is seen to tailor healthcare decision-making more closely to the characteristics of individual patients, and thus as a step towards making healthcare more personalized and effective.” A new overview on the potential uses and benefits of RWE has been published by PharmExec.com, authored (more…)

Welcome to the CanREValue Website

/0 Comments/in /by
CanREValue is happy to announce our initial website is now live! Still under construction, we expect the Working Group and Resources sections to be populated in early 2019, and we will also upload copies of presentations & abstracts on the Knowledge Translation page. Should you have any questions about the (more…)

FDA’s RWE Framework

/0 Comments/in /by
Earlier in December the FDA released a new framework outlining how they will use Real World Evidence (RWE) and Real World Data (RWD) in decision making for new drugs and biologics.  Under the new framework, the FDA will use the following three criteria to evaluate RWE/RWD: 1. Whether the RWD are fit (more…)